Skip to Content

Eventide Healthcare & Life Sciences I ETIHX

Analyst rating as of
NAV / 1-Day Return
26.60  /  0.15 %
Total Assets
1.3 Bil
Adj. Expense Ratio
1.290%
Expense Ratio
1.290%
Fee Level
High
Longest Manager Tenure
9.40 years
Category
Health
Investment Style
Small Growth
Min. Initial Investment
100,000
Status
Open
TTM Yield
2.42%
Turnover
62%
Premium

Morningstar’s Analysis

Will ETIHX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Co-Portfolio Managers Added to Eventide Gilead and Healthcare & Life Sciences; No Ratings Changes

Senior Analyst

Analyst Note

| |

Eventide Asset Management announced that, effective Jan. 1, 2022, it is promoting Anant Goel to co-portfolio manager of Eventide Gilead ETGLX, Joy Ghosh to co-portfolio manager of Eventide Healthcare & Life Sciences ETNHX, and Andrew Singer to co-portfolio manager of Eventide Dividend Opportunities ETNDX. Goel and Ghosh join firm co-founder Finny Kuruvilla, who was previously the only named manager of Eventide Gilead and Healthcare & Life Sciences, while Singer joins Dolores Bamford, who has been the only named manager of the Dividend Opportunities fund since 2019.

Unlock our full analysis with Morningstar Premium